According to the Shanghai Pharmaceutical announcement, Changzhou Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Registration Certificate” for esomeprazole magnesium enteric capsules issued by the State Drug Administration, and the drug was approved for production. The drug is suitable for gastroesophageal reflux disease, the elimination of Helicobacter pylori, etc. The company has invested about 5.19 million yuan in research and development expenses for this drug. In 2025, hospitals in mainland China purchased the drug for 639 million yuan. The approval of the drug is beneficial to expanding market share, but there is uncertainty about its sales falling short of expectations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.